Loading...

Cann Group

ASX:CAN
Snowflake Description

Exceptional growth potential with excellent balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
CAN
ASX
A$312M
Market Cap
  1. Home
  2. AU
  3. Pharmaceuticals & Biotech
Company description

Cann Group Limited engages in research and development, cultivation and production, manufacturing, clinical evaluation, and distribution/supply of medicinal cannabis for a range of diseases and medical conditions in Australia. The last earnings update was 96 days ago. More info.


Add to Portfolio Compare Print
  • Cann Group has significant price volatility in the past 3 months.
CAN Share Price and Events
7 Day Returns
-2.2%
ASX:CAN
2%
AU Pharmaceuticals
2.5%
AU Market
1 Year Returns
-36.4%
ASX:CAN
-26.2%
AU Pharmaceuticals
5%
AU Market
CAN Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Cann Group (CAN) -2.2% -7.4% 26.9% -36.4% - -
AU Pharmaceuticals 2% -4.8% 0.4% -26.2% -40.3% -25.1%
AU Market 2.5% 2.4% 4.8% 5% 19.3% 8.7%
1 Year Return vs Industry and Market
  • CAN underperformed the Pharmaceuticals industry which returned -26.2% over the past year.
  • CAN underperformed the Market in Australia which returned 5% over the past year.
Price Volatility
CAN
Industry
5yr Volatility vs Market

Value

 Is Cann Group undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Cann Group to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Cann Group.

ASX:CAN Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 1 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 7.1%
Perpetual Growth Rate 10-Year AU Government Bond Rate 2.3%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for ASX:CAN
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year AU Govt Bond Rate 2.3%
Equity Risk Premium S&P Global 6%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.69
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.693 (1 + (1- 30%) (0.01%))
0.795
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.8
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.31% + (0.8 * 5.96%)
7.08%

Discounted Cash Flow Calculation for ASX:CAN using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Cann Group is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

ASX:CAN DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (AUD, Millions) Source Present Value
Discounted (@ 7.08%)
2019 -30.50 Analyst x1 -28.48
2020 -64.60 Analyst x1 -56.34
2021 -52.60 Analyst x1 -42.84
2022 20.90 Analyst x1 15.90
2023 57.60 Analyst x1 40.91
2024 94.29 Est @ 63.7% 62.55
2025 136.99 Est @ 45.29% 84.87
2026 181.37 Est @ 32.39% 104.93
2027 223.76 Est @ 23.37% 120.89
2028 261.91 Est @ 17.05% 132.15
Present value of next 10 years cash flows A$434.54
ASX:CAN DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= A$261.91 × (1 + 2.31%) ÷ (7.08% – 2.31%)
A$5,620.13
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= A$5,620.13 ÷ (1 + 7.08%)10
A$2,835.71
ASX:CAN Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= A$434.54 + A$2,835.71
A$3,270.26
Equity Value per Share
(AUD)
= Total value / Shares Outstanding
= A$3,270.26 / 139.80
A$23.39
ASX:CAN Discount to Share Price
Calculation Result
Value per share (AUD) From above. A$23.39
Current discount Discount to share price of A$2.24
= -1 x (A$2.24 - A$23.39) / A$23.39
90.4%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Cann Group is available for.
Intrinsic value
>50%
Share price is A$2.24 vs Future cash flow value of A$23.39
Current Discount Checks
For Cann Group to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Cann Group's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Cann Group's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Cann Group's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Cann Group's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
ASX:CAN PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in AUD A$-0.06
ASX:CAN Share Price ** ASX (2019-05-24) in AUD A$2.24
Australia Pharmaceuticals Industry PE Ratio Median Figure of 6 Publicly-Listed Pharmaceuticals Companies 20.33x
Australia Market PE Ratio Median Figure of 542 Publicly-Listed Companies 16.39x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Cann Group.

ASX:CAN PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ASX:CAN Share Price ÷ EPS (both in AUD)

= 2.24 ÷ -0.06

-38.34x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Cann Group is loss making, we can't compare its value to the AU Pharmaceuticals industry average.
  • Cann Group is loss making, we can't compare the value of its earnings to the Australia market.
Price based on expected Growth
Does Cann Group's expected growth come at a high price?
Raw Data
ASX:CAN PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -38.34x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
66.1%per year
Global Pharmaceuticals Industry PEG Ratio Median Figure of 117 Publicly-Listed Pharmaceuticals Companies 1.55x
Australia Market PEG Ratio Median Figure of 358 Publicly-Listed Companies 1.43x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Cann Group, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Cann Group's assets?
Raw Data
ASX:CAN PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in AUD A$0.59
ASX:CAN Share Price * ASX (2019-05-24) in AUD A$2.24
Australia Pharmaceuticals Industry PB Ratio Median Figure of 26 Publicly-Listed Pharmaceuticals Companies 3.26x
Australia Market PB Ratio Median Figure of 1,680 Publicly-Listed Companies 1.66x
ASX:CAN PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ASX:CAN Share Price ÷ Book Value per Share (both in AUD)

= 2.24 ÷ 0.59

3.82x

* Primary Listing of Cann Group.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Cann Group is overvalued based on assets compared to the AU Pharmaceuticals industry average.
X
Value checks
We assess Cann Group's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Cann Group has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Cann Group expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
66.1%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Cann Group expected to grow at an attractive rate?
  • Cann Group's earnings growth is expected to exceed the low risk savings rate of 2.3%.
Growth vs Market Checks
  • Cann Group's earnings growth is expected to exceed the Australia market average.
  • Cann Group's revenue growth is expected to exceed the Australia market average.
Annual Growth Rates Comparison
Raw Data
ASX:CAN Future Growth Rates Data Sources
Data Point Source Value (per year)
ASX:CAN Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts 66.1%
ASX:CAN Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 61.8%
Australia Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 51.4%
Australia Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 32.1%
Australia Market Earnings Growth Rate Market Cap Weighted Average 6.9%
Australia Market Revenue Growth Rate Market Cap Weighted Average 3.2%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
ASX:CAN Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in AUD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
ASX:CAN Future Estimates Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-06-30 190 56 54 1
2022-06-30 159 42 36 1
2021-06-30 101 -15 11 1
2020-06-30 4 -22 -18 1
2019-06-30 3 -12 -10 1
ASX:CAN Past Financials Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income *
2018-12-31 2 -7 -8
2018-09-30 2 -5 -6
2018-06-30 2 -4 -5
2018-03-31 1 -3 -4
2017-12-31 0 -2 -3
2017-09-30 0 -2 -3
2017-06-30 0 -2 -3
2016-06-30 0 -1 -1

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Cann Group's earnings are expected to grow significantly at over 20% yearly.
  • Cann Group's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
ASX:CAN Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Cann Group Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:CAN Future Estimates Data
Date (Data in AUD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-06-30 0.38 0.38 0.38 1.00
2022-06-30 0.25 0.25 0.25 1.00
2021-06-30 0.08 0.08 0.08 1.00
2020-06-30 -0.13 -0.13 -0.13 1.00
2019-06-30 -0.07 -0.07 -0.07 1.00
ASX:CAN Past Financials Data
Date (Data in AUD Millions) EPS *
2018-12-31 -0.06
2018-09-30 -0.05
2018-06-30 -0.04
2018-03-31 -0.04
2017-12-31 -0.04
2017-09-30 -0.04
2017-06-30 -0.05
2016-06-30 -0.05

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Cann Group is expected to efficiently use shareholders’ funds in the future (Return on Equity greater than 20%).
X
Future performance checks
We assess Cann Group's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Australia market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Australia market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Cann Group has a total score of 6/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Cann Group performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Cann Group's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Cann Group does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Cann Group's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Cann Group's 1-year growth to the Global Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Cann Group's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Cann Group Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:CAN Past Revenue, Cash Flow and Net Income Data
Date (Data in AUD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 1.55 -8.16 10.94 1.25
2018-09-30 1.53 -6.44 9.11 1.01
2018-06-30 1.50 -4.73 7.29 0.78
2018-03-31 0.78 -3.93 4.83 0.61
2017-12-31 0.05 -3.13 2.46 0.47
2017-09-30 0.03 -2.86 2.05 0.51
2017-06-30 0.01 -2.59 1.64 0.55
2016-06-30 0.01 -1.46 1.10 0.35
2015-06-30 0.01 -4.18 3.67 0.44

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Cann Group has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Cann Group has efficiently used its assets last year compared to the AU Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Cann Group improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Cann Group's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Cann Group has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Cann Group's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Cann Group's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Cann Group is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Cann Group's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Cann Group's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 4097.5x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Cann Group Company Filings, last reported 4 months ago.

ASX:CAN Past Debt and Equity Data
Date (Data in AUD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 81.98 0.02 72.56
2018-09-30 81.98 0.02 72.56
2018-06-30 85.87 0.02 79.65
2018-03-31 85.87 0.02 79.65
2017-12-31 69.57 0.02 66.52
2017-09-30 69.57 0.02 66.52
2017-06-30 14.66 0.02 11.11
2016-06-30 1.69 0.00 1.34
2015-06-30 0.65 0.00 0.45
  • Cann Group's level of debt (0%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if Cann Group's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Cann Group has sufficient cash runway for more than 3 years based on current free cash flow.
  • Cann Group has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 70.2% each year.
X
Financial health checks
We assess Cann Group's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Cann Group has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Cann Group's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Cann Group dividends.
If you bought A$2,000 of Cann Group shares you are expected to receive A$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Cann Group's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Cann Group's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
ASX:CAN Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Global Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 144 Stocks 2.9%
Australia Market Average Dividend Yield Market Cap Weighted Average of 414 Stocks 4.2%
Australia Minimum Threshold Dividend Yield 10th Percentile 1.5%
Australia Bottom 25% Dividend Yield 25th Percentile 2.6%
Australia Top 25% Dividend Yield 75th Percentile 5.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

ASX:CAN Future Dividends Estimate Data
Date (Data in A$) Dividend per Share (annual) Avg. No. Analysts
2023-06-30
2022-06-30
2021-06-30
2020-06-30
2019-06-30

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Cann Group has not reported any payouts.
  • Unable to verify if Cann Group's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Cann Group's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Cann Group has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Cann Group's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.5%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Cann Group afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Cann Group has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Cann Group's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Peter Crock
COMPENSATION A$993,626
TENURE AS CEO 3 years
CEO Bio

Mr. Peter Crock, B.Ag.Sci (Hons), MBA has been Chief Executive Officer at CANN Group Limited since May 23, 2016. Mr. Crock is an experienced public company senior manager with strong skills in marketing and technology development. In a 28 year career at Nufarm Limited, he held senior management roles in marketing, business development and information technology, heading up its new technologies division which involved the licensing and commercial development of several new agribusiness technologies. He has project managed the successful integration of newly acquired businesses and has extensive experience working with regulators in Australia and overseas.

CEO Compensation
  • Peter's compensation has increased whilst company is loss making.
  • Peter's remuneration is higher than average for companies of similar size in Australia.
Management Team

Peter Crock

TITLE
Chief Executive Officer
COMPENSATION
A$994K
TENURE
3 yrs

Richard Baker

TITLE
Company Secretary & CFO

Steven Notaro

TITLE
Legal and Regulatory Affairs Officer
Board of Directors Tenure

Average tenure of the Cann Group board of directors in years:

3.1
Average Tenure
  • The tenure for the Cann Group board of directors is about average.
Board of Directors

Allan McCallum

TITLE
Non-Executive Chairman
COMPENSATION
A$33K

Philip Robert Jacobsen

TITLE
Deputy Chairman
COMPENSATION
A$22K

Doug Rathbone

TITLE
Independent Non-Executive Director
COMPENSATION
A$22K
AGE
72
TENURE
4.2 yrs

Geoff Pearce

TITLE
Independent Non-Executive Director
COMPENSATION
A$22K
TENURE
3.1 yrs

Neil Belot

TITLE
Non-Executive Director
COMPENSATION
A$7K
TENURE
1.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (A$) Value (A$)
23. Dec 18 Buy Philip Robert Jacobsen Individual 20. Dec 18 20. Dec 18 10,000 A$1.83 A$18,291
18. Dec 18 Buy Philip Robert Jacobsen Individual 14. Dec 18 18. Dec 18 20,000 A$2.06 A$41,242
X
Management checks
We assess Cann Group's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Cann Group has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

What Kind Of Investor Owns Most Of Cann Group Limited (ASX:CAN)?

Every investor in Cann Group Limited (ASX:CAN) should be aware of the most powerful shareholder groups. … Cann Group is not a large company by global standards. … Taking a look at our data on the ownership groups (below), it's seems that.

Simply Wall St -

Imagine Owning Cann Group (ASX:CAN) And Wondering If The 40% Share Price Slide Is Justified

Cann Group isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. … When a company doesn't make profits, we'd generally expect to see good revenue growth. … Cann Group grew its revenue by 2842% over the last year.

Simply Wall St -

Did Cann Group Limited (ASX:CAN) Insiders Buy Up More Shares?

So we'll take a look at whether insiders have been buying or selling shares in Cann Group Limited (ASX:CAN). … But logic dictates you should pay some attention to whether insiders are buying or selling shares. … Cann Group Insider Transactions Over The Last Year.

Simply Wall St -

These Factors Make Cann Group Limited (ASX:CAN) An Interesting Investment

Cann Group Limited (ASX:CAN) is a company with exceptional fundamental characteristics. … Upon building up an investment case for a stock, we should look at various aspects. … In the case of CAN, it

Simply Wall St -

Cann Group Limited (ASX:CAN) Is Expected To Breakeven

Cann Group Limited's (ASX:CAN):. … Cann Group Limited, an agribusiness company, focuses on breeding, cultivating, manufacturing, and selling medicinal cannabis for a range of diseases and medical conditions in Australia. … With the latest financial year loss of -AU$2.59m and a trailing-twelve month of -AU$3.13m, the AU$396.79m market-cap amplifies its loss by moving further away from its breakeven target.

Simply Wall St -

When Will Cann Group Limited (ASX:CAN) Become Profitable?

I’ve put together a brief outline of industry analyst expectations for CAN, its year of breakeven and its implied growth rate. … ASX:CAN Past Future Earnings May 15th 18 Underlying developments driving CAN’s growth isn’t the focus of this broad overview, however, bear in mind that by and large a pharma company has lumpy cash flows which are contingent on the drug and stage of product development the business is in. … So, a high growth rate is not out of the ordinary, particularly when a company is in a period of investment.

Simply Wall St -

Cann Group Limited (ASX:CAN): How Much Growth Is Left In Healthcare?

Not surprisingly, this rate is more than double the growth rate of the Australian stock market as a whole. … ASX:CAN PE PEG Gauge Nov 30th 17 The pharmaceutical sector's PE is currently hovering around 24x, above the broader Australian stock market PE of 17x. … Although its growth has delivered lower growth relative to its pharmaceutical peers in the near term, the market may be pessimistic on the stock, leading to a potential undervaluation.

Simply Wall St -

Does Cann Group Limited's (ASX:CAN) CEO Pay Reflect Performance?

View our latest analysis for Cann Group What has been the trend in CAN's earnings? … Normally I'd use market cap and profit as factors determining performance, however, CAN's negative earnings reduces the effectiveness of this method. … To find out more about CAN's governance, look through our infographic report of the company's board and management.

Simply Wall St -

Has Cann Group Limited (ASX:CAN) Got Enough Cash To Cover Its Short-Term Obligations?

Zero-debt allows substantial financial flexibility, especially for small-cap companies like Cann Group Limited (ASX:CAN), as the company does not have to adhere to strict debt covenants. … Check out our latest analysis for Cann Group Is financial flexibility worth the lower cost of capital? … Choosing financial flexibility over capital returns make sense if CAN is a high-growth company.

Simply Wall St -

Company Info

Description

Cann Group Limited engages in research and development, cultivation and production, manufacturing, clinical evaluation, and distribution/supply of medicinal cannabis for a range of diseases and medical conditions in Australia. The company was founded in 2015 and is headquartered in Bundoora, Australia.

Details
Name: Cann Group Limited
CAN
Exchange: ASX
Founded: 2015
A$311,763,470
139,804,247
Website: http://www.canngrouplimited.com
Address: Cann Group Limited
Walter and Eliza Hall Institute of Medical Research,
4 Research Avenue,
Bundoora,
Victoria, 3083,
Australia
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ASX CAN Ordinary Shares Australian Securities Exchange AU AUD 04. May 2017
OTCPK CNGG.F Ordinary Shares Pink Sheets LLC US USD 04. May 2017
DB CVJ Ordinary Shares Deutsche Boerse AG DE EUR 04. May 2017
Number of employees
Current staff
Staff numbers
0
Cann Group employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/24 10:36
End of day share price update: 2019/05/24 00:00
Last estimates confirmation: 2019/04/09
Last earnings filing: 2019/02/17
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/06/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.